The resignation of FDA Commissioner Marty Makary in May 2026, following internal clashes, left Kyle Diamantas as acting commissioner and opened a broad search for a permanent successor. With the White House reviewing several candidates amid ongoing vetting, trader odds remain dispersed across low-single-digit probabilities for names including Diamantas, Stephen Hahn, Sara Brenner, Brett Giroir, and Grace Graham, plus a slim chance of no announcement by year-end. Senate confirmation requirements, the need to align with administration health priorities, and uncertainty over timing continue to limit consolidation behind any single contender in this wide-open field.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedStephen Hahn <1%
Kyle Diamantas <1%
Sara Brenner <1%
No announcement by December 31 <1%
$33,305 Vol.
$33,305 Vol.
Dec 30, 2026
Kyle Diamantas
1%
Stephen Hahn
1%
Brett Giroir
<1%
Grace Graham
<1%
Sara Brenner
1%
No announcement by December 31
<1%
Stephen Hahn <1%
Kyle Diamantas <1%
Sara Brenner <1%
No announcement by December 31 <1%
$33,305 Vol.
$33,305 Vol.
Dec 30, 2026
Kyle Diamantas
$6,786 Vol.
1%
Stephen Hahn
$4,144 Vol.
1%
Brett Giroir
$5,265 Vol.
<1%
Grace Graham
$6,683 Vol.
<1%
Sara Brenner
$7,418 Vol.
1%
No announcement by December 31
$3,007 Vol.
<1%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.The resignation of FDA Commissioner Marty Makary in May 2026, following internal clashes, left Kyle Diamantas as acting commissioner and opened a broad search for a permanent successor. With the White House reviewing several candidates amid ongoing vetting, trader odds remain dispersed across low-single-digit probabilities for names including Diamantas, Stephen Hahn, Sara Brenner, Brett Giroir, and Grace Graham, plus a slim chance of no announcement by year-end. Senate confirmation requirements, the need to align with administration health priorities, and uncertainty over timing continue to limit consolidation behind any single contender in this wide-open field.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Market Opened: May 12, 2026, 7:59 PM ET
Volume
$33,305End Date
Dec 31, 2026Market Opened
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.The resignation of FDA Commissioner Marty Makary in May 2026, following internal clashes, left Kyle Diamantas as acting commissioner and opened a broad search for a permanent successor. With the White House reviewing several candidates amid ongoing vetting, trader odds remain dispersed across low-single-digit probabilities for names including Diamantas, Stephen Hahn, Sara Brenner, Brett Giroir, and Grace Graham, plus a slim chance of no announcement by year-end. Senate confirmation requirements, the need to align with administration health priorities, and uncertainty over timing continue to limit consolidation behind any single contender in this wide-open field.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volume
$33,305End Date
Dec 31, 2026Market Opened
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...The resignation of FDA Commissioner Marty Makary in May 2026, following internal clashes, left Kyle Diamantas as acting commissioner and opened a broad search for a permanent successor. With the White House reviewing several candidates amid ongoing vetting, trader odds remain dispersed across low-single-digit probabilities for names including Diamantas, Stephen Hahn, Sara Brenner, Brett Giroir, and Grace Graham, plus a slim chance of no announcement by year-end. Senate confirmation requirements, the need to align with administration health priorities, and uncertainty over timing continue to limit consolidation behind any single contender in this wide-open field.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions